Perbandingan antara Efektivitas Penggunaan Fluorokuinolon VS Beta-Laktam dan/atau Makrolida pada Pasien Pneumonia Komunitas Rawat Inap: Sebuah Kajian Literatur

Andi Amelia Sari Riandika; Nanang Munif Yasin; Titik Nuryastuti

doi:10.22146/farmaseutik.v21i1.94339

Perbandingan antara Efektivitas Penggunaan Fluorokuinolon VS Beta-Laktam dan/atau Makrolida pada Pasien Pneumonia Komunitas Rawat Inap: Sebuah Kajian Literatur

https://doi.org/10.22146/farmaseutik.v21i1.94339

Andi Amelia Sari Riandika⁽¹⁾, Nanang Munif Yasin^(2*), Titik Nuryastuti⁽³⁾

(1) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(2) Departemen Farmakologi & Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Departemen Mikrobiologi Klinik, Fakultas Kedokteran, Kesehatan Masyarakat, & Keperawatan, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Pneumonia komunitas merupakan infeksi pneumonia yang diperoleh dari lingkungan masyarakat atau dari luar rumah sakit, di mana rejimen antibiotik pasien dengan pneumonia komunitas adalah monoterapi fluorokuinolon (FK) atau dengan kombinasi beta laktam (BL) dan makrolida (MD). Review ini membandingkan efektivitas penggunaan antara monoterapi FK dengan BL±MD pada pasien dewasa pneumonia komunitas yang dirawat inap. Studi kontrol terandomisasi dilibatkan dalam review artikel ini mengikuti daftar checklist PRISMA. Hasil review dari 6 studi kontrol terandomisasi menunjukkan bahwa monoterapi dengan FK memiliki efektivitas yang serupa dengan terapi rejimen BL+MD pada pasien pneumonia komunitas mild hingga moderate. Monoterapi BL, rejimen BL+MD, dan monoterapi FK memiliki efektivitas yang serupa pada pasien pneumonia komunitas mild hingga moderate dan yang dirawat inap di ruangan non intensive care unit (non-ICU). Monoterapi MD tidak kalah dengan monoterapi FK dari segi efektivitas pada pasien pneumonia komunitas bakterial mild hingga moderate. Kesimpulannya, antara monoterapi FK, monoterapi BL, monoterapi MD, dan kombinasi BL+MD memiliki profile efektivitas yang serupa.

Keywords

pneumonia komunitas; fluorokuinolon; beta laktam; makrolida; efektivitas

Full Text:

PDF

References

Barrera, C. M., Mykietiuk, A., Metev, H., Nitu, M. F., Karimjee, N., Doreski, P. A., Mitha, I., Tanaseanu, C. M., Molina, J. M. D., Antonovsky, Y., Van Rensburg, D. J., Rowe, B. H., Flores-Figueroa, J., Rewerska, B., Clark, K., Keedy, K., Sheets, A., Scott, D., Horwith, G., … Oldach, D. (2016). Efficacy and Safety of Oral Solithromycin versus Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia: A Global, Double-blind, Multicentre, Randomised, Active-controlled, Non-inferiority Trial (SOLITAIRE-ORAL). The Lancet Infectious Diseases, 16(4), 421–430. https://doi.org/10.1016/S1473-3099(16)00017-7

Basilim, A., Wali, H., Rabaan, A. A., & Eljaaly, K. (2022). Efficacy of Empiric Macrolides versus Fluoroquinolones in Community-Acquired Pneumonia Associated with Atypical Bacteria: A Meta-Analysis. Respiratory Medicine and Research, 82, 1–5. https://doi.org/10.1016/j.resmer.2022.100931

Choi, S. H., Cesar, A., Snow, T. A. C., Saleem, N., Arulkumaran, N., & Singer, M. (2023). Respiratory Fluoroquinolone Monotherapy vs. β-Lactam Plus Macrolide Combination Therapy for Hospitalized Adults with Community-Acquired Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. International Journal of Antimicrobial Agents, 62(3), 106905. https://doi.org/10.1016/j.ijantimicag.2023.106905

Cilloniz, C., Martin-Loeches, I., Garcia-Vidal, C., Jose, A. S., & Torres, A. (2016). Microbial etiology of pneumonia: Epidemiology, diagnosis and resistance patterns. International Journal of Molecular Sciences, 17(12). https://doi.org/10.3390/ijms17122120

File, T. M., Rewerska, B., Vucinić-Mihailović, V., Gonong, J. R. V., Das, A. F., Keedy, K., Taylor, D., Sheets, A., Fernandes, P., Oldach, D., & Jamieson, B. D. (2016). SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. Clinical Infectious Diseases, 63(8), 1007–1016. https://doi.org/10.1093/cid/ciw490

Fogarty, C., Siami, G., Kohler, R., File, T. M., Tennenberg, A. M., Olson, W. H., Wiesinger, B. A., Scott Marshall, J. A., Oross, M., & Kahn, J. B. (2004). Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin-Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adul. Clinical Infectious Diseases, 38(SUPPL. 1). https://doi.org/10.1086/378406

Horita, N., Otsuka, T., Haranaga, S., Namkoong, H., Miki, M., Miyashita, N., Higa, F., Takahashi, H., Yoshida, M., Kohno, S., & Kaneko, T. (2016). Beta-lactam plus Macrolides or Beta-Lactam Alone for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Respirology, 21(7), 1193–1200. https://doi.org/10.1111/resp.12835

Izadi, M., Dadsetan, B., Najafi, Z., Jafari, S., Mazaheri, E., Dadras, O., Heidari, H., SeyedAlinaghi, S., & Voltarelli, F. (2018). Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patient. Recent Patents on Anti-Infective Drug Discovery, 13(3).

Kyprianou, M., Dakou, K., Aktar, A., Aouina, H., Behbehani, N., Dheda, K., Juvelekian, G., Khattab, A., Mahboub, B., Nyale, G., Oraby, S., Sayiner, A., Shibl, A., El Deen, M. A. T., Unal, S., Zubairi, A. B. S., Davidson, R., & Giamarellos-Bourboulis, E. J. (2023). Macrolides for Better Resolution of Community-Acquired Pneumonia: A Global Meta-Analysis of Clinical Outcomes with Focus on Microbial Aetiology. International Journal of Antimicrobial Agents, 62(4), 106942. https://doi.org/10.1016/j.ijantimicag.2023.106942

Lim, W. S. (2022). Pneumonia-Overview. Encyclopedia of Respiratory Medicine, 4, 185–197. https://doi.org/10.1016/B978-0-12-801238-3.11636-8

López-véjar, C. E., Cruz, L. C., Meraz-ortega, R., Román-flores, A., Geuguer-chávez, L., Pedro-gonzález, A., Lozano-nuevo, J. J., & Rubio-guerra, A. (2013). Effectiveness of Levofloxacin in NAC 2013 Medigraphic (Spanyol). Med Int Mex, 29, 587–594.

Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 200(7), 45–67. https://doi.org/10.1164/rccm.201908-1581ST

National Institute for Health and Care Excellent. (2022). Pneumonia in adults: diagnosis and management. In NICE Guideline.

Postma, D. F., van Werkhoven, C. H., van Elden, L. J. R., Thijsen, S. F. T., Hoepelman, A. I. M., Kluytmans, J. A. J. W., Boersma, W. G., Compaijen, C. J., van der Wall, E., Prins, J. M., Oosterheert, J. J., & Bonten, M. J. M. (2015). Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults. New England Journal of Medicine, 372(14), 1312–1323. https://doi.org/10.1056/nejmoa1406330

Raz-Pasteur, A., Shasha, D., & Paul, M. (2015). Fluoroquinolones or Macrolides Alone versus Combined with β-lactams for Adults with Community-Acquired Pneumonia: Systematic Review and Meta-Analysis. International Journal of Antimicrobial Agents, 46(3), 242–248. https://doi.org/10.1016/j.ijantimicag.2015.04.010

Sitong, L., Tong, X., Ma, Y., Wang, D., Huang, J., Zhang, L., Wu, M., Wang, L., Liu, T., & Fan, H. (2019). Respiratory Fluoroquinolones Monotherapy vs. β-Lactams with or without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis. Frontiers in Pharmacology, 10(MAY). https://doi.org/10.3389/fphar.2019.00489

Xu, L. Y., Wang, C. C., Peng, X. X., Jiao, Y., Zhao, C. Z., Zhang, L., & Ma, L. (2022). Empirical Antibiotic Treatment Strategies for Community-Acquired Pneumonia: A Network Meta-analysis. Journal of Global Antimicrobial Resistance, 30, 1–9. https://doi.org/10.1016/j.jgar.2022.05.009

Yadegarynia, D., Tehrani, S., Nejad, F. M., Shojaeian, F., & Keyvanfar, A. (2022). Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study. Iranian Journal of Microbiology, 14(4), 458–465. https://doi.org/10.18502/ijm.v14i4.10231

DOI: https://doi.org/10.22146/farmaseutik.v21i1.94339